Funding for this research was provided by:
European Research Council (669237, 681712)
Vetenskapsrådet (2015-02830, 2013-8717)
Received: 16 July 2019
Accepted: 18 July 2019
First Online: 26 July 2019
: CEB is a member of the GSK Immunology Catalyst, serves on the scientific advisory board of Nodthera, is a consultant for Syncona and a co-founder of Polypharmakos. KB has served as a consultant or at advisory boards for Alector, Alzheon, CogRx, Biogen, Lilly, Novartis and Roche Diagnostics, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg, IS has served as a consultant for Takeda. HZ has served at scientific advisory boards for Roche Diagnostics, Wave, Samumed and CogRx and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg, all unrelated to the work presented in this paper. All the other authors declare no competing interests.